Inotec raises $33m Series C to accelerate US expansion
The funding, led by existing investors – Cambridge duo Amadeus Capital Partners and Jonathan Milner’s Meltwind + Puhua Capital and the Wealth Club – marks a major milestone in the company’s mission to heal every chronic wound and improve patients’ lives on a global scale.
The proceeds will be strategically used to secure national reimbursement in the United States for NATROX O₂, ensuring broader accessibility for patients across the US.
The money will also support the expansion of the company’s leadership team, strengthening its global capabilities to drive future growth and innovation.
Founded with a commitment to address critical gaps in wound care, Inotec AMD has focused on developing advanced topical oxygen therapy solutions that enhance healing and improve patients’ quality of life.
The flagship cTOT product, NATROX O₂, delivers a continuous flow of oxygen directly to the wound, creating an optimal environment for healing. NATROX O₂ has set new standards in wound care, providing a non-invasive, wearable solution that is accessible for both patients and healthcare providers.
"Inotec AMD's global success is rooted in our dedication to patient-centric innovation, especially through our work with NATROX O₂," said Craig Kennedy, CEO of Inotec AMD.
“This latest round of financing underscores the confidence our investors have in our vision and our ability to make a significant impact in the wound care space providing life-altering improvements for our patients.”
With the new capital, Inotec AMD is poised to accelerate its strategic initiatives, including the essential step of obtaining national US reimbursement for NATROX O₂.
This achievement will pave the way for greater adoption of its cTOT technology, enabling healthcare providers to offer a simple, user-friendly therapy designed to accelerate healing, even in wounds that have persisted for years, such as diabetic foot ulcers, venous leg ulcers, pressure injuries, and non-healing surgical or traumatic wounds.
More than 100 million people worldwide suffer from wounds that will not heal. In the US, wound care costs the health services an estimated $97 billion annually, with chronic wounds making up $50bn of that expense. In the UK, the NHS spends as much on wound care as it does on oncology, mostly because chronic wounds can’t be healed reliably – until now.
Pierre Socha, Partner, Amadeus Capital Partners, says: “Amadeus backed Natrox from inception and it is fulfilling to see this best-in-class technology now available in a growing number of markets.
“NATROX O₂ is already authorised to sell in 46 countries. It is becoming the reference advance therapy for the healing of chronic wounds across private and public health systems globally. Securing national coverage in the US is another step forward for the team.”
With NATROX O₂’s regulatory approvals in over 25 countries, Inotec AMD continues expanding access to innovative wound care solutions globally.
